Clinical Data

business targets illustration
Biotech

Lynk targets the JAK pot with phase 3 rheumatoid arthritis win

Lynk’s JAK1 trial hit its primary endpoint, boosting the prospects of a candidate designed to avoid the adverse events caused by existing drugs.
Nick Paul Taylor Jan 12, 2026 8:45am
An arrow incrementally going up stairs before pointing straight up Blue background

Hutchmed heats up autoimmune race with phase 3 win

Jan 7, 2026 4:39am
photo of a quiver of arrows

Arrowhead takes aim at obesity with early gene silencing data

Jan 6, 2026 10:19am
Graphic image of an arrow nailing the bullseye of a target

Alumis beams as pivotal data on Sotyktu rival drive stock surge

Jan 6, 2026 9:05am
An envelope with rejected mark Vector illustration

FDA shares CRL for Sanofi MS drug mere weeks after rebuff

Jan 6, 2026 4:30am
obesity overweight weight loss weigh

MetaVia weighs in with 9% loss to enter the obesity ring

Jan 5, 2026 10:44am